The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Long-term follow-up of psilocybin-facilitated smoking cessation
Open accessAbstract
BACKGROUND: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. OBJECTIVES: To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. METHODS: The present report describes biologically verified smoking abstinence outcomes of the previous pilot study at ≥12 months, and related data on subjective effects of psilocybin. RESULTS: All 15 participants completed a 12-month follow-up, and 12 (80%) returned for a long-term (≥16 months) follow-up, with a mean interval of 30 months (range = 16-57 months) between target-quit date (i.e., first psilocybin session) and long-term follow-up. At 12-month follow-up, 10 participants (67%) were confirmed as smoking abstinent. At long-term follow-up, nine participants (60%) were confirmed as smoking abstinent. At 12-month follow-up 13 participants (86.7%) rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives. CONCLUSION: These results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence. The present study adds to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction. Further research investigating psilocybin-facilitated treatment of substance use disorders is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously noted, mindfulness practices facilitate behavioral change by enabling individuals to identify triggers and habitual responses, whereas psychedelic therapy can amplify this awareness, resulting in even deeper behavioral transformations [33].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Classic psychedelics, such as synthetic LSD and psilocybin, which is found in certain mushrooms, have shown promise as aids in psychotherapy e.g., for mood disorders and substance dependence [1, 5, 33].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There is emerging evidence from early phase trials of nicotine dependence (14)”
From Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use (2024) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Psilocybin-assisted psychotherapy (PAT) also appears to be safe and potentially efficacious for substance use disorders, based on early trials for nicotine and alcohol use disorders [14,15], with little evidence of harmful use in the community [16].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“Psilocybin occasioned mystical experiences are defined by acute feelings of unity, sacredness, a noetic quality, positive mood, transcendence of space/time, and ineffability (6), and have previously shown a significant association with successful psilocybinfacilitated smoking cessation outcomes at 6-month followup (11…”
Self-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1×
“psilocybin-facilitated treatment of alcohol dependence (24), the present findings indicate that 5-HT2AR agonists may hold therapeutic potential in treating a variety of”
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citationPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 4×
“Consistent with previously published data (4), no participants reported an increase in bothersome visual”
InfluentialSelf-citationGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Self-citationMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Self-citationValidation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637
Self-citationLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- World Health Organization, 2011, WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco
Cited by
Sorted by citations
Items 101–200 of 694
Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders
Thomas, K., Malcolm, B., & Lastra, D. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1320734 · Cited by 75
van Mulukom, V., Patterson, R. E., & van Elk, M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05568-y · Cited by 62
Lutkajtis, A., & Evans, J. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00232 · Cited by 67
Wolff, M., Mertens, L. J., Walter, M., Enge, S., & Evens, R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073758 · Cited by 58
Kopra, E. I., Ferris, J., WINSTOCK, A. R., Kuypers, K. P. C., Young, A. H., & Rucker, J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158245 · Cited by 67
In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin
Thomann, J., Kolaczynska, K. E., Stoeckmann, O. V., Rudin, D., Vizeli, P., Hoener, M. C., Pryce, C. R., Vollenweider, F. X., Liechti, M. E., & Duthaler, U. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1391689 · Cited by 59
Mendes, F. R., Costa, C. D. S., Wiltenburg, V. D., Morales-Lima, G., Fernandes, J. A. B., & Filev, R. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100025 · Cited by 67
Kolaczynska, K. E., Liechti, M. E., & Duthaler, U. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122486 · Cited by 58
Microdosing psilocybin for chronic pain: a case series
Lyes, M., Yang, K. H., Castellanos, J. P., & Furnish, T. J. (2022) · Pain · doi:10.1097/j.pain.0000000000002778 · Cited by 56
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
Jaster, A. M., & González‐Maeso, J. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02274-x · Cited by 56
Holze, F., Singh, N., Liechti, M. E., & D’Souza, D. C. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.01.007 · Cited by 62
Luoma, J. B., Sabucedo, P., Eriksson, J., Gates, N., & Pilecki, B. C. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.10.003 · Cited by 56
The economics of psychedelic-assisted therapies: A research agenda
Marseille, E. A., Bertozzi, S., & Kahn, J. G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1025726 · Cited by 62
Perkins, D., Opaleye, E. S., Šimonová, H., Bouso, J. C., Tófoli, L. F., Coelho, N. L. G., Schubert, V., & Sarris, J. J. (2021) · Drug and Alcohol Review · doi:10.1111/dar.13348 · Cited by 54
Psychosis and psychedelics: Historical entanglements and contemporary contrasts
Friesen, P. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221129116 · Cited by 61
Opioid use disorder: current trends and potential treatments
Lee, Y. K., Gold, M. S., Blum, K., Thanos, P. K., Hanna, C., & Fuehrlein, B. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1274719 · Cited by 59
Foldi, C. J., Liknaitzky, P., Williams, M., & Oldfield, B. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00043 · Cited by 51
Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics
Glowacki, D. R., Wonnacott, M. D., Freire, R., Glowacki, B. R., Gale, E. M., Pike, J. E., de Haan, T., Chatziapostolou, M., & Metatla, O. (2020) · Proceedings of the 2020 CHI Conference on Human Factors in Computing Systems · doi:10.1145/3313831.3376649 · Cited by 54
The Effects of Hallucinogens on Gene Expression
Martin, D. A., & Nichols, C. D. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_479 · Cited by 59
Whelan, A., & Johnson, M. I. (2018) · Pain Management · doi:10.2217/pmt-2017-0068 · Cited by 51
Self-citationWießner, I., Falchi-Carvalho, M., Palhano-Fontes, F., Feilding, A., Ribeiro, S. T. G., & Tófoli, L. F. (2021) · Psychological Medicine · doi:10.1017/s0033291721002531 · Cited by 54
Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications
O’Callaghan, C. C., Hubik, D. J., Dwyer, J. L., Williams, M. L., & Ross, M. (2020) · Journal of Music Therapy · doi:10.1093/jmt/thaa006 · Cited by 57
Yaden, D. B., Berghella, A. P., Regier, P. S., Garcia‐Romeu, A., Johnson, M. W., & Hendricks, P. S. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103380 · Cited by 55
Self-citationEffinger, D. P., Quadir, S. G., Ramage, M. C., Cone, M. G., & Herman, M. A. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02414-5 · Cited by 51
Kiilerich, K. F., Lorenz, J., Scharff, M. B., Speth, N., Brandt, T. G., Czurylo, J., Xiong, M., Jessen, N. S., Casado-Sainz, A., Shalgunov, V., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02280-z · Cited by 48
Conn, K., Milton, L. K., Huang, K., Munguba, H., Ruuska, J., Lemus, M. B., Greaves, E., Homman‐Ludiye, J., Oldfield, B. J., & Foldi, C. J. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02575-9 · Cited by 58
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism
Mitchell, J., & Anderson, B. T. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01656-7 · Cited by 55
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms
Calder, A. E., Mock, S., Friedli, N., Pasi, P., & Hasler, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.05.008 · Cited by 52
Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice
Fadahunsi, N., Lund, J. T., Breum, A. W., Mathiesen, C. V., Larsen, I. B., Knudsen, G. M., Klein, A. B., & Clemmensen, C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02103-9 · Cited by 47
Group psychedelic therapy: empirical estimates of cost-savings and improved access
Marseille, E. A., Stauffer, C. S., Agrawal, M., Thambi, P. M., Roddy, K., Mithoefer, M. C., Bertozzi, S., & Kahn, J. G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1293243 · Cited by 50
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Bezo, A., Piolino, P., & Benyamina, A. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106086 · Cited by 53
Schindler, E. A. D., Wallace, R. M., Sloshower, J., & D’Souza, D. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00177 · Cited by 51
Política de drogas e Saúde Coletiva: diálogos necessários
Gomes-Medeiros, D., de Faria, P. H., Campos, G. W. D. S., & Tófoli, L. F. (2019) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00242618 · Cited by 47
Selby, P. L., & Zawertailo, L. A. (2022) · New England Journal of Medicine · doi:10.1056/nejmcp2032393 · Cited by 47
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 52
Naturalistic Psychedelic Use: A World Apart from Clinical Care
Glynos, N. G., Fields, C. W., Barron, J., Herberholz, M., Kruger, D. J., & Boehnke, K. F. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2108356 · Cited by 51
Kałużna, A., Schlosser, M., Craste, E. G., Stroud, J., & Cooke, J. E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00199 · Cited by 53
Bornemann, J., Close, J. B., Spriggs, M. J., Carhart-Harris, R. L., & Roseman, L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.735427 · Cited by 48
Jaster, A. M., Elder, H., Marsh, S. A., Revenga, M. D. L. F., Negus, S. S., & González‐Maeso, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06092-x · Cited by 45
Mindfulness meditation and psychedelics: potential synergies and commonalities
Holas, P., & Kamińska, J. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00551-8 · Cited by 43
“As previously noted, mindfulness practices facilitate behavioral change by enabling individuals to identify triggers and habitual responses, whereas psy-chedelic therapy can amplify this awareness, resulting in even deeper behavioral transformations [33].”
BackgroundThe need for establishing best practices and gold standards in psychedelic medicine
Feduccia, A. A., Agin-Liebes, G., Price, C. M., Grinsell, N., Paradise, S., & Rabin, D. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.083 · Cited by 44
Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin
Kargbo, R. B., Sherwood, A. M., Walker, A., Cozzi, N. V., Dagger, R. E., Sable, J., O’Hern, K., Kaylo, K. W., Patterson, T., Tarpley, G., et al. (2020) · ACS Omega · doi:10.1021/acsomega.0c02387 · Cited by 45
Studies with psychedelic drugs in human volunteers
Sellers, E. M., Romach, M. K., & Leiderman, D. B. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.029 · Cited by 42
Mertens, L. J., Koslowski, M., Betzler, F., Evens, R., Gilles, M., Jungaberle, A., Jungaberle, H., Majić, T., Ströhle, A., Wolff, M., et al. (2022) · Neuroscience Applied · doi:10.1016/j.nsa.2022.100104 · Cited by 41
Morgan, C. J. A., McAndrew, A., Stevens, T., Nutt, D., & Lawn, W. (2016) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.10.009 · Cited by 42
Koslowski, M., Johnson, M. W., Gründer, G., & Betzler, F. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00401-8 · Cited by 42
Self-citationVilliger, D., & Trachsel, M. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2022-108816 · Cited by 43
Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy
Thal, S. B., Bright, S. J., Sharbanee, J. M., Wenge, T., & Skeffington, P. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.617224 · Cited by 38
Set, Setting, and Clinical Trials: Colonial Technologies and Psychedelics
Dumit, J., & Sanabria, E. (2022) · Springer eBooks · doi:10.1007/978-981-16-7084-8_15 · Cited by 39
Psychedelic treatment of functional neurological disorder: a systematic review
Butler, M., Seynaeve, M., Nicholson, T. R., Pick, S., Kanaan, R., Lees, A. J., Young, A. H., & Rucker, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320912125 · Cited by 39
Niles, H. F., Fogg, C., Kelmendi, B., & Lazenby, M. (2021) · BMC Palliative Care · doi:10.1186/s12904-021-00889-x · Cited by 39
Do psychedelics change beliefs?
McGovern, H. T., Leptourgos, P., Hutchinson, B. T., & Corlett, P. R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06153-1 · Cited by 40
Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice
Alper, K., Cange, J., Sah, R., Schreiber-Gregory, D., Sershen, H. W., & Vinod, K. Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1074633 · Cited by 41
Castro Santos, H., & Gama Marques, J. (2021) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000128 · Cited by 37
Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder
Markopoulos, A., Inserra, A., De Gregorio, D., & Gobbi, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.749068 · Cited by 46
Healy, C. J., Lee, K. A., & D'Andrea, W. M. (2021) · Chronic Stress · doi:10.1177/24705470211029881 · Cited by 39
Catalysts for change: the cellular neurobiology of psychedelics
Banks, M. I., Zahid, Z., Jones, N., Sultan, Z. W., & Wenthur, C. J. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-05-0340 · Cited by 45
Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
Rieser, N. M., Herdener, M., & Preller, K. H. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_284 · Cited by 37
Psilocybin history, action and reaction: A narrative clinical review
Sharma, P., Nguyen, Q. A., Matthews, S. J., Carpenter, E., Matthews, D. B., Patten, C. A., & Hammond, C. J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190858 · Cited by 44
Argento, E., Braschel, M. C., Walsh, Z., Socias, M. E., & Shannon, K. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118798610 · Cited by 38
Cannabis-induced oceanic boundlessness
Earleywine, M., Ueno, L. F., Mian, M. N., & Altman, B. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121997099 · Cited by 36
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Gründer, G., & Jungaberle, H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1486-7386 · Cited by 39
The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders
Collins, G. T., Gerak, L. R., & France, C. P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.023 · Cited by 36
Psilocybin’s effects on cognition and creativity: A scoping review
Bonnieux, J. N., VanderZwaag, B., Premji, Z., Garcia‐Romeu, A., & García-Barrera, M. A. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231179801 · Cited by 38
Self-citationSøndergaard, A., Madsen, M. K., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.948729 · Cited by 37
Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review
Piper, T., Small, F., Brown, S., Kelleher, M., Mitcheson, L., Rucker, J., Young, A. H., & Marsden, J. (2025) · Addiction · doi:10.1111/add.16762 · Cited by 35
Psilocybin-Assisted Compassion Focused Therapy for Depression
Pots, W. T. M., & Chakhssi, F. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.812930 · Cited by 35
Jones, G. M., Lipson, J., & Nock, M. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-14809-3 · Cited by 33
A Brief Historical Overview of Psychedelic Research
Geyer, M. A. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.11.003 · Cited by 39
Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review
Ziff, S., Stern, B., Lewis, G., Majeed, M., & Gorantla, V. R. (2022) · Cureus · doi:10.7759/cureus.21944 · Cited by 48
Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation
Johnson, M. W. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_327 · Cited by 37
Self-citationPsilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
Prouzeau, D., Conejero, I., Voyvodic, P. L., Bécamel, C., Abbar, M., & López‐Castromán, J. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01361-0 · Cited by 37
Argento, E., Socias, M. E., Hayashi, K., Choi, J., Mackay, L., Christie, D., Milloy, M., & DeBeck, K. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103518 · Cited by 35
Davis, A. K., Xin, Y., Sepeda, N. D., & Averill, L. A. (2023) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2023.2220874 · Cited by 36
The Effects of Psychedelics on Neuronal Physiology
Hatzipantelis, C. J., & Olson, D. E. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-020923 · Cited by 39
Oppong‐Damoah, A., Curry, K. E., Blough, B. E., Rice, K. C., & Murnane, K. S. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05328-7 · Cited by 33
Dynamic Brain Connectivity in Resting State Functional MR Imaging
Jalilianhasanpour, R., Ryan, D. H., Agarwal, S., Beheshtian, E., Gujar, S. K., Pillai, J. J., & Sair, H. I. (2020) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2020.09.004 · Cited by 32
Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine
O’Shaughnessy, D. M., Berlowitz, I., Rodd, R., Sarnyai, Z., & Quirk, F. H. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320986634 · Cited by 32
Cavanna, F., Pallavicini, C., Milano, V., Cuiule, J. I., Tella, R. D., González, P., & Tagliazucchi, E. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00172 · Cited by 34
Giving Consent to the Ineffable
Villiger, D. (2024) · Neuroethics · doi:10.1007/s12152-024-09545-6 · Cited by 32
The renaissance in psychedelic research: What do preclinical models have to offer
Murnane, K. S. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.08.003 · Cited by 35
Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil
Daldegan‐Bueno, D., Maia, L. O., Massarentti, C. M., & Tófoli, L. F. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06063-2 · Cited by 34
Psychedelic Cognition—The Unreached Frontier of Psychedelic Science
Bălăeţ, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.832375 · Cited by 34
Sharma, R., Batchelor, R., & Sin, J. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2190319 · Cited by 30
Psilocybin occasioned mystical‐type experiences
James, E., Robertshaw, T. L., Hoskins, M. D., & Sessa, B. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2742 · Cited by 36
Efficacité des psychédéliques en psychiatrie, une revue systématique
Berkovitch, L., Roméo, B., Karila, L., Gaillard, R., & Benyamina, A. (2021) · L Encéphale · doi:10.1016/j.encep.2020.12.002 · Cited by 35
The therapeutic potential of psychedelics: the European regulatory perspective
Butlen‐Ducuing, F., McCulloch, D. E.-W., Haberkamp, M., Mattila, T. K., Bałkowiec-Iskra, E., Aislaitner, G., Balabanov, P., Lundberg, J., Stenbæk, D. S., Elferink, A. J. A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00264-7 · Cited by 29
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 33
The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item
Strickland, J. C., Garcia‐Romeu, A., & Johnson, M. W. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0046 · Cited by 28
Self-citationSafety pharmacology of acute psilocybin administration in healthy participants
Straumann, I., Holze, F., Becker, A., Ley, L., Halter, N., & Liechti, M. E. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104060 · Cited by 30
Floris, G., Dabrowski, K. R., Zanda, M. T., & Daws, S. E. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02788-y · Cited by 33
Animal Behavior in Psychedelic Research
Odland, A. U., Kristensen, J. L., & Andreasen, J. T. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000590 · Cited by 30
Boehnke, K. F., Cox, K., Weston, C. L., Herberholz, M., Glynos, N. G., Kolbman, N., Fields, C. W., Barron, J., & Kruger, D. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1224551 · Cited by 30
When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research
Jacobs, E., Murphy-Beiner, A., Rouiller, I., Nutt, D. J., & Spriggs, M. J. (2023) · Neuroethics · doi:10.1007/s12152-023-09536-z · Cited by 31
Tripping over the other: Could psychedelics increase empathy?
Blatchford, E., Bright, S. J., & Engel, L. B. (2020) · Journal of Evolutionary Psychology · doi:10.1556/2054.2020.00136 · Cited by 30
Cox, D. J., Garcia‐Romeu, A., & Johnson, M. W. (2021) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2021.1910830 · Cited by 27
Self-citationEffects of classic psychedelic drugs on turbulent signatures in brain dynamics
Cruzat, J., Perl, Y. S., Escrichs, A., Vohryzek, J., Timmermann, C., Roseman, L., Luppi, A. I., Ibáñez, A. M., Nutt, D. J., Carhart-Harris, R. L., et al. (2022) · Network Neuroscience · doi:10.1162/netn_a_00250 · Cited by 26
Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy
Mocanu, V., Mackay, L., Christie, D., & Argento, E. (2022) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-022-00468-0 · Cited by 31
Epigenetic Mechanisms of Rapid-Acting Antidepressants
Inserra, A., Campanale, A., Rezai, T., Romualdi, P., & Rubino, T. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03055-y · Cited by 27
Bernal, A. M. O., Raison, C. L., Lancelotta, R., & Davis, A. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1049643 · Cited by 32
Metadata
- Authors
- Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Corresponding author
- Johnson, Matthew W.
- Venue
- The American Journal of Drug and Alcohol Abuse
- Publisher
- Informa UK Limited
- Published
- 2016-07-21
- Volume
- 43
- Issue
- 1
- Pages
- 55-60
- ISSN
- 0095-2990 (ISSN-L)
- 1097-9891
- PMC
- PMC5641975
- OpenAlex
- W2506717582
- Cited by
- 696
- References
- 23
- Citations by year
- 2026: 53 · 2025: 100 · 2024: 89 · 2023: 112 · 2022: 131 · 2021: 63 · 2020: 83 · 2019: 17 · 2018: 31 · 2017: 13 · 2016: 3
- FWCI
- 17.16
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-01-20)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The American Journal of Drug and Alcohol Abuse (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (R01DA003889)
- Beckley Foundation (N/A)
- Heffter Research Institute (N/A)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- psilocybin, smoking cessation, smoking abstinence, long-term follow-up, cognitive behavioral therapy, classic psychedelics, addiction treatment, spiritual experience
- MeSH terms
- Combined Modality Therapy, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Pilot Projects, Psilocybin, Cognitive Behavioral Therapy, Smoking Cessation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
